ClinicalTrials.gg
CompletedNCT07214766Updated Jul 17, 2026

A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants

A Phase 1 interventional study of Trastuzumab in Healthy Participants, sponsored by Genentech, Inc.. Completed at 4 sites in United States. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
331
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

This two-part study will evaluate the bioequivalence, safety, and tolerability of a single SC dose of trastuzumab administered via handheld syringe/syringe pump (HHS/SP) with infusion set (IS) and an on-body delivery system (OBDS).

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Within (BMI) range 18 to 38 kilogram per meter square (kg/m2), inclusive. Body weight \<=100 kg
  • (LVEF) >= 55 percent (%) measured by echocardiogram (ECHO)
  • Negative test result for drugs of abuse
  • Negative test result for surface antigen, virus (HCV), or (HIV) antibody screen
  • Negative test for latent Tuberculosis (TB) infection by QuantiFERON® TB Gold
  • Agree to use and will refrain from sperm donation

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, respiratory, gastrointestinal, immunological, neurological, or psychiatric disorder; acute infection; or other unstable medical disease
  • History of moderate or severe allergic, anaphylactic, or other reactions to chimeric, human, or humanized antibodies or fusion proteins
  • Known sensitivity to recombinant hyaluronidase or other form of hyaluronidase
  • History or presence of atrial fibrillation
  • History of any or clinically relevant cardiac condition
  • History or presence of clinically significant (ECG) abnormalities
  • History of uncontrolled hypertension, hyperlipidemia, thyroid disorder, or diabetes
  • Family history of clinically significant and clinically relevant hypersensitivity, allergy, or severe cardiac diseases
  • History of previous anti-cancer treatments including pertuzumab, trastuzumab, anthracyclines, or any cardiotoxic drugs
  • History of active or latent TB, regardless of treatment history
  • Poor peripheral venous access
  • History or presence of any , with the exception of completely excised basal cell or squamous cell carcinoma of the skin
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
331 participants (actual)

Study arms

  • Experimental
    Part 1

    Participants will receive formulation 1 of trastuzumab SC via OBDS or HHS/SP with IS.

    Drug: Trastuzumab

  • Experimental
    Part 2

    Participants will receive formulation 2 of trastuzumab SC via OBDS or HHS/SP with IS.

    Drug: Trastuzumab

Interventions

  • Trastuzumab will be administered to participants as a solution for injection.

06

What researchers measure

Primary outcomes

  1. Part 1: Area Under the Concentration-Time Curve from Hour 0 to 21 days Postdose (AUC0-21days) of Trastuzumab

    Time frame: Up to Day 57

  2. Part 1: Maximum Observed Concentration (Cmax) of Trastuzumab

    Time frame: Up to Day 57

  3. Part 2: AUC0-21days of Trastuzumab

    Time frame: Up to Day 57

  4. Part 2: Cmax of Trastuzumab

    Time frame: Up to Day 57

Secondary outcomes

  1. Percentage of Participants with Adverse Events (AEs)

    Time frame: Up to Day 57

07

Study locations

4 sites
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
  • Fortrea Clinical Research Unit - Daytona Beach
    Daytona Beach, Florida 32117-5116, United States
  • QPS Bio-Kinetic
    Springfield, Missouri 65802-4842, United States
  • Fortrea Clinical Research Unit - Dallas
    Dallas, Texas 75247, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Jul 2026, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2025
First posted
Oct 9, 2025
StartActual
Oct 17, 2025
Primary completionActual
Jul 3, 2026
CompletionActual
Jul 3, 2026
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07214766
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
Oct 17, 2025
Primary completion
Jul 3, 2026
Completion
Jul 3, 2026
Last update
Jul 17, 2026

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion